A huge thank you to everyone who joined our Continuous Education Programme (CEP) at United in Vision 2026.
The session brought together patient leaders, researchers, industry representatives, and advocates for a thought-provoking discussion on the role of Patient Experience Data (PED) across the retinal research and development lifecycle.
Throughout the morning, speakers explored topics ranging from patient engagement legislation and health technology assessment to real-world registries, therapy development, and the co-design of meaningful endpoints. A common theme emerged across every presentation and discussion: research is stronger when patients are involved from the very beginning.
What made the session particularly special was the quality of the discussion. Participants shared valuable perspectives, challenged assumptions, raised important questions, and highlighted practical ways to ensure the patient experience is meaningfully embedded in research, innovation, regulation, and decision-making.
We are incredibly grateful to our speakers, moderators, attendees, and partners at Foundation Fighting Blindness for helping create such an engaging and collaborative programme.
The conversations don’t end here. The ideas, challenges, and opportunities discussed during the CEP will continue to shape how we work together to ensure that patient voices remain at the heart of retinal research and innovation.
Image 1:
Jason Menzo, CEO of the Foundation Fighting Blindness, leads an interactive discussion during the RI CEP at United in Vision 2026.
Image 2:
CEP participants engage in discussion and knowledge-sharing during the Q&A session led by Jason Menzo, CEO of the Foundation Fighting Blindness.
Image 3:
Dr Daniel Chung from Beacon Therapeutics presents on the importance of co-designing meaningful clinical trial endpoints with patients during the CEP.
